United States Health

Apogee Therapeutics (NASDAQ:APGE) solidified its clinical roadmap for 2026 on Monday, reporting a year-end cash position of $902.9 million.

Xeris Biopharma Holdings (NASDAQ:XERS), a Chicago-based specialty pharmaceutical company focused on therapies for rare endocrine and metabolic diseases, on Monday reported net income of $11.1 million for its fourth quarter ended December 31, 2025.

uniQure (NASDAQ:QURE) entered 2026 with a dual narrative of clinical progress and regulatory complexity.

Compugen (NASDAQ:CGEN) delivered a transformative fiscal 2025, reporting a sharp pivot to profitability and a significantly bolstered balance sheet.

Zymeworks (NASDAQ:ZYME) reported a significant narrowing of its annual losses and a double-digit jump in revenue on Monday, driven by the continued maturation of its oncology-focused licensing portfolio.

RadNet (NASDAQ:RDNT) reported record fourth-quarter and full-year 2025 results today, underscoring the success of its dual-track strategy to dominate both physical outpatient imaging and the burgeoning clinical AI market.

Belite Bio (NASDAQ:BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, today announced positive topline results from its pivotal Phase 3 DRAGON trial evaluating tinlarebant, an oral retinol binding protein 4 (RBP4) antagonist, for the treatment of adolescent Stargardt disease.

Merck (NYSE:MRK) unveiled groundbreaking final results from the Phase 3 KEYNOTE-B96 trial today at the ESGO 2026 Congress, demonstrating that a Keytruda-based regimen can extend the lives of patients facing one of the most aggressive forms of ovarian cancer.

ALX Oncology Holdings (NASDAQ:ALXO) reported fourth-quarter and full-year 2025 results on Friday, highlighting a fundamental shift toward a biomarker-driven strategy that could redefine patient selection for its immuno-oncology pipeline.

BrightSpring Health Services (NASDAQ:BTSG) posted a decisive fourth-quarter beat on Friday, capping a year of aggressive expansion with a return to full-year profitability.

Moderna (NASDAQ:MRNA) secured a landmark regulatory victory on Friday as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for mCOMBRIAX (mRNA-1083).

ANI Pharmaceuticals (NASDAQ:ANIP) posted record fourth-quarter net revenue of $247.1 million on Friday, a 29.6% increase over the same period last year.